Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Understanding the impact of United States policy spillovers on cancer drug reimbursement decisions internationally

EF 2021-22

Résumé
To achieve World Health Organization (WHO) Sustainable Development Goal (SDG) 3.8 for universal health coverage, governments must ensure access to safe, effective, quality, and affordable medicines. It is known that US drug policy decisions "spill over" to other countries. Canadian decision-makers have highlighted how the unconstrained US market creates additional pressure to expand access to medications with marginal benefit. The problem with US policy spillover is that there has been a long-documented decline of regulatory standards, where medicines are often approved without robust supporting evidence. Despite the importance of understanding cross-border influences, little is known about how US policies impact regulatory decisions abroad. It is hypothesized that US policies negatively impact other countries by creating pressure to expand access to drugs with unproven benefits, while increasing prices from a decentralized, non-price controlled market, therefore constraining public health care systems abroad. This study will involve a two-phased, mixed-methods approach utilizing an international survey, quantitative modelling, and document review. First, a cross-sectional survey will be developed to elicit perspective from decision-makers internationally. The second aim of this survey is to identify two countries for an in-depth case study. Quantitative modelling (time series analysis) will measure the impact of US cancer drug approvals on reimbursement decisions. To contextualize these findings, a document review of existing policies and literature will also be conducted. This research will provide an important evaluation of US pharmaceutical policy in foreign countries. By quantifying potential policy spillovers, countries will understand influences on domestic health systems. This information is vital to ensure medicines reimbursed reflect population needs and scarce resources are allocated to high-value therapeutics to improve cancer outcomes worldwide.
Programme
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
455218
Name
Jenei Kristina
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Health Services and Policy Research
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Understanding the impact of United States policy spillovers on cancer drug reimbursement decisions internationally
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Cancer; Decision Making; Essential Medicines; Global Health; Health Policy; Health Services Research; Health Technology Assessment; Low And Middle Income Countries; Priority Setting; World Health Organization
Abstract
To achieve World Health Organization (WHO) Sustainable Development Goal (SDG) 3.8 for universal health coverage, governments must ensure access to safe, effective, quality, and affordable medicines. It is known that US drug policy decisions "spill over" to other countries. Canadian decision-makers have highlighted how the unconstrained US market creates additional pressure to expand access to medications with marginal benefit. The problem with US policy spillover is that there has been a long-documented decline of regulatory standards, where medicines are often approved without robust supporting evidence. Despite the importance of understanding cross-border influences, little is known about how US policies impact regulatory decisions abroad. It is hypothesized that US policies negatively impact other countries by creating pressure to expand access to drugs with unproven benefits, while increasing prices from a decentralized, non-price controlled market, therefore constraining public health care systems abroad. This study will involve a two-phased, mixed-methods approach utilizing an international survey, quantitative modelling, and document review. First, a cross-sectional survey will be developed to elicit perspective from decision-makers internationally. The second aim of this survey is to identify two countries for an in-depth case study. Quantitative modelling (time series analysis) will measure the impact of US cancer drug approvals on reimbursement decisions. To contextualize these findings, a document review of existing policies and literature will also be conducted. This research will provide an important evaluation of US pharmaceutical policy in foreign countries. By quantifying potential policy spillovers, countries will understand influences on domestic health systems. This information is vital to ensure medicines reimbursed reflect population needs and scarce resources are allocated to high-value therapeutics to improve cancer outcomes worldwide.
Competitiondate
202110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Jenei, Kristina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~